HIV-1 Nucleic Acid Probe Hybridization Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting lymphadenopathy-associated virus (LAV) and related viruses are limited, particularly in detecting specific parts of the genomic DNA that are not always detectable by immunological methods, and lack versatility in recognizing whole viruses in a non-disintegrated state.
Innovation Solution
Development of cloned DNA sequences, such as LAV 75, LAV 82, and LAV 13, which contain specific restriction sites and correspond to the R and U3 regions of the LTR, allowing for the creation of stable probes that can hybridize with LAV genomic RNA and DNA, enabling detection in various biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If immunological methods are used to detect LAV, then detection of expression products is achieved, but detection of specific parts of genomic DNA and whole viruses in non-disintegrated state is limited
Solution Approach 1:
The patent introduces cloned DNA sequences as intermediary probes that hybridize with LAV genomic RNA and DNA. These probes serve as mediators between the detection system and the viral genetic material, enabling direct detection of specific genomic regions regardless of expression product availability. The probes contain specific restriction sites and correspond to R and U3 regions of LTR, allowing reliable detection through hybridization rather than relying on immunological detection of expression products.
2Measurement precision
If cloned DNA sequences with specific restriction sites are developed, then detection specificity is improved, but method complexity increases
Solution Approach 1:
The patent segments the LAV genome into specific regions of interest (R region, U3 region of LTR) and develops separate cloned DNA probes for each segment. This segmentation allows targeted detection of specific genomic regions with high specificity. Each probe is designed with particular restriction sites (HindIII, SacI, BglII, KpnI, XhoI, BamHI) that enable precise identification of viral DNA sequences without requiring complex overall methodology.
Solution Approach 2:
The patent performs preliminary cloning and characterization of DNA sequences containing specific restriction sites before actual detection. The cloned sequences are prepared in advance with known restriction patterns and genomic correspondence, so that during detection, simple hybridization procedures can be used. This preliminary preparation of probes with defined characteristics simplifies the actual detection process while maintaining high specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These probes provide a versatile means for detecting LAV and related viruses, including their RNA and integrated DNA forms, offering improved specificity and the ability to identify specific parts of the genomic DNA, even when expression products are not directly detectable by immunological methods.
Implementation Method 1
cloned DNA sequences, such as LAV 75, LAV 82, and LAV 13, which contain specific restriction sites and correspond to the R and U3 regions of the LTR, allowing for the creation of stable probes that can hybridize with LAV genomic RNA and DNA
Data Source
AI summary
This invention is in the field of lymphadenopathy virus. This invention relates to a diagnostic means and method to detect the presence of DNA, RNA, or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them, and the proteins expressed.